Questo sito utilizza cookies tecnici (necessari) e analitici.
Proseguendo nella navigazione accetti l'utilizzo dei cookie.

Science and Innovation in Healthcare: event at the Embassy of Italy


12 December 2023 (18.00-19.30)
By invitation only.

Innovation in healthcare is accelerating in particular in the field of digital medicine and advances like artificial intelligence, gene therapy and vaccine are transforming the way diseases are detected, diagnosed and treated. During this event, the speakers will discuss how technological advances may revolutionise healthcare by early detecting, diagnosing and treating diseases. 


Daniel Hochhauser:  Research and Technologies: strategies for innovation in oncology

Sergio Quezada: From research discoveries to development of novel therapies

Mariam Jamal-Hanjani: How Darwinian evolution drives disease progression

Alberto Mantovani: Immunity and Inflammation, from Cancer to COVID-19


Daniel Hochhauser
Daniel Hochhauser is a Kathleen Ferrier professor and consultant medical oncologist. Following postgraduate medical training in London and Oxford, he was awarded a DPhil at the Institute of Molecular Medicine in Oxford. Subsequently he completed specialist training at the Memorial Sloan-Kettering Cancer Center in New York before appointment as a consultant and senior lecturer in 1996.

Daniel is the Head of the Department of Oncology at UCL, Clinical Director of the Cancer Research UK-UCL Centre and Lead of the Cancer Theme of the UCLH Biomedical Research Centre. His special interest is in gastrointestinal medical oncology and he practices at a number of top clinics in the capital including his NHS base, University College London Hospital. He is dedicated to research, focusing on the development of novel therapeutics and early phase clinical studies.

Sergio Quezada
Sergio Quezada is a Professor of Cancer Immunology and Immunotherapy at University College London Cancer Institute and Chief Scientific Officer of Achilles Therapeutics. He earned his undergraduate degree in Biochemistry from the P. Universidad Católica de Chile and a Ph.D. from Dartmouth Medical School in the US. In 2004, he joined the laboratory of the Nobel Laureate Prof James Allison at MSKCC. His work at UCL focuses in cancer immunology, tumour microenvironment, regulatory T cells and immune checkpoint blockade. Sergio’s research work lead to creation of a spin off company, Achilles therapeutics, a clinical stage company delivering personalised T cell therapies against cancer. Sergio was a recipient of Dartmouth’s John W. Strohbern Medal, the Cancer Research Institute new investigator award, a CRUK Career Development Fellowship and a CRUK Senior Cancer Research Fellowship.

Mariam Jamal-Hanjani
Mariam Jamal-Hanjani is a Thoracic Medical Oncologist and Group Leader at the UCL Cancer Institute in London. Her research is focussed on the biological processes driving metastatic disease, including genomic drivers of tumour dissemination, tumour-and host-initiated mediators of catabolic states suggestive of cachexia, and failure of the adaptive immune system. She is Principal Investigator of the national TRACERx lung cancer evolution study, Chief Investigator of the national PEACE research autopsy programme, and Chief Scientific Investigator of the first-in-human CHIRON study investigating the clinical activity of autologous clonal neoantigen T cells in patients with advanced non-small cell lung cancer.

Alberto Mantovani
Alberto Mantovani, MD, is the Scientific Director of Humanitas Research Hospital, President and Founder of Humanitas Research Foundation (Fondazione Humanitas per la Ricerca) and Emeritus professor of Pathology at Humanitas University, in Milan. He is also Chair of Inflammation and Therapeutic Innovation at the William Harvey Research Institute of the Queen Mary University in London. Alberto Mantovani is recognized among his peers as a forerunner and a “founding father” of the renaissance of the inflammation-cancer connection. More recently he focused on COVID-19, contributing to the identification of genetic associations and of a novel severity biomarker. He has received several national and international awards, such as the Triennial OECI Award from the Organization of the European Cancer Institutes, the Robert Koch Award and the CIMT Lifetime Achievement Award.


Please note that you may be photographed or filmed during this event. If you have any objections, please advise the Embassy by writing to